Talis Biomedical Corp
Talis Biomedical Corporation does not have significant operations. Previously, it was involved in the development of medical devices for infectious diseases and other conditions at the point of care in the United States. The company evaluates strategic alternatives, including acquisition, merger, reverse merger, divestiture of assets, a voluntary reorganization, dissolution or liquidation, and li… Read more
Talis Biomedical Corp (TLIS) - Total Liabilities
Latest total liabilities as of June 2024: $24.07 Million USD
Based on the latest financial reports, Talis Biomedical Corp (TLIS) has total liabilities worth $24.07 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Talis Biomedical Corp - Total Liabilities Trend (2018–2023)
This chart illustrates how Talis Biomedical Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Talis Biomedical Corp Competitors by Total Liabilities
The table below lists competitors of Talis Biomedical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PExA AB (publ)
F:FA0
|
Germany | €2.07 Million |
|
Oxford Cannabinoid Technologies Holdings Plc
PINK:OCTHF
|
USA | $840.00K |
|
X2M Connect Ltd
AU:X2M
|
Australia | AU$9.26 Million |
|
GECI International SA
PA:ALGEC
|
France | €10.79 Million |
|
AEMLF
PINK:AEMLF
|
USA | $366.29K |
|
Eastern Resources Ltd
AU:EFE
|
Australia | AU$217.98K |
Liability Composition Analysis (2018–2023)
This chart breaks down Talis Biomedical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Talis Biomedical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Talis Biomedical Corp (2018–2023)
The table below shows the annual total liabilities of Talis Biomedical Corp from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $25.56 Million | -39.94% |
| 2022-12-31 | $42.55 Million | +33.59% |
| 2021-12-31 | $31.85 Million | -89.62% |
| 2020-12-31 | $306.98 Million | +554.91% |
| 2019-12-31 | $46.87 Million | -26.04% |
| 2018-12-31 | $63.38 Million | -- |